RU2004132198A - Терапевтическое применение селективных ингибиторов pde10 - Google Patents

Терапевтическое применение селективных ингибиторов pde10 Download PDF

Info

Publication number
RU2004132198A
RU2004132198A RU2004132198/15A RU2004132198A RU2004132198A RU 2004132198 A RU2004132198 A RU 2004132198A RU 2004132198/15 A RU2004132198/15 A RU 2004132198/15A RU 2004132198 A RU2004132198 A RU 2004132198A RU 2004132198 A RU2004132198 A RU 2004132198A
Authority
RU
Russia
Prior art keywords
disorder
neurodegenerative
selective
spiky
neurons
Prior art date
Application number
RU2004132198/15A
Other languages
English (en)
Other versions
RU2303259C2 (ru
Inventor
Лоррейн Энн ЛЕБЕЛ (US)
Лоррейн Энн ЛЕБЕЛ
Франк Сэмьюэль МЕННИТИ (US)
Франк Сэмьюэль МЕННИТИ
Кристофер Джозеф ШМИДТ (US)
Кристофер Джозеф ШМИДТ
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/139,183 external-priority patent/US20030018047A1/en
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2004132198A publication Critical patent/RU2004132198A/ru
Application granted granted Critical
Publication of RU2303259C2 publication Critical patent/RU2303259C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)

Claims (9)

1. Способ определения наличия у химического соединения активности селективного ингибитора PDE10, включающий:
a) введение химического соединения в культуру медиальных шиповатых нейронов; и
b) измерение возможного повышения фосфорилирования CREB в культуре; повышение фосфорилирования CREB, тем самым показывает, что соединение, использованное в стадии (a) обладает селективной ингибиторной активностью в отношении PDE10.
2. Способ определения наличия у химического соединения активности селективного ингибитора PDE10, включающий:
a) введение химического соединения в культуру медиальных шиповатых нейронов; и
b) измерение возможного повышения количества продуцируемого GABA медиальными шиповатыми нейронами в указанной культуре;
повышение продукции GABA указанными медиальными шиповатыми нейронами, тем самым показывает, что соединение, использованное в стадии (a) обладает селективной ингибиторной активностью в отношении PDE10.
3. Способ лечения расстройства, выбранного из обсессивно/компульсивного расстройства, синдрома Туретта и других тиков у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для лечения указанного расстройства.
4. Способ лечения нейродегенеративного расстройства или состояния у млекопитающего, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для лечения указанного расстройства или состояния.
5. Способ по п. 4, где нейродегенеративное расстройство или состояние выбрано из болезни Паркинсона; болезни Гентингтона; деменции, например, деменции при болезни Альцгеймера, мультиинфарктной деменции, деменции при СПИДе; и фронто-темпоральной деменции; нейродегенеративного процесса, связанного с травмой головного мозга; нейродегенеративного процесса, связанного с инсультом, нейродегенеративного процесса, связанного с инфарктом мозга; нейродегенеративного процесса, вызванного гипогликемией; нейродегенеративного процесса, связанного с эпилептическими припадками; нейродегенеративного процесса, связанного с нейротоксическим отравлением; и множественной системной атрофии.
6. Способ по п. 4, где нейродегенеративное расстройство или состояние включает в себя нейродегенерацию медиальных шиповатых нейронов млекопитающих.
7. Способ по п. 5, где нейродегенеративным расстройством или состоянием является болезнь Гентингтона.
8. Способ лечения двигательного расстройства, выбранного из болезни Гентингтона и дискинезии, связанной с терапевтическим применением агонистов допамина, у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для ингибирования PDE10.
9. Способ лечения расстройства, выбранного из обсессивно/компульсивного расстройства, синдрома Туретта и других тиков у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для ингибирования PDE10.
RU2004132198/15A 2002-05-03 2003-04-22 Терапевтическое применение селективных ингибиторов pde10 RU2303259C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/139,183 US20030018047A1 (en) 2001-04-20 2002-05-03 Therapeutic use of selective PDE10 inhibitors
US10/139,183 2002-05-03
US10/177,018 US20030032579A1 (en) 2001-04-20 2002-06-20 Therapeutic use of selective PDE10 inhibitors
US10/177,018 2002-06-20

Publications (2)

Publication Number Publication Date
RU2004132198A true RU2004132198A (ru) 2005-04-20
RU2303259C2 RU2303259C2 (ru) 2007-07-20

Family

ID=29406263

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004132198/15A RU2303259C2 (ru) 2002-05-03 2003-04-22 Терапевтическое применение селективных ингибиторов pde10

Country Status (16)

Country Link
US (2) US20030032579A1 (ru)
EP (1) EP1504118A2 (ru)
JP (1) JP2005524402A (ru)
KR (1) KR20040106455A (ru)
CN (1) CN1668761A (ru)
AU (1) AU2003222395A1 (ru)
BR (1) BR0309746A (ru)
CA (1) CA2484600A1 (ru)
HR (1) HRP20041029A2 (ru)
IL (1) IL164778A0 (ru)
MX (1) MXPA04010777A (ru)
NO (1) NO20044470L (ru)
PL (1) PL373943A1 (ru)
RU (1) RU2303259C2 (ru)
TW (1) TWI269812B (ru)
WO (1) WO2003093499A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657540C2 (ru) * 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86591C2 (ru) * 2003-06-30 2009-05-12 Алтана Фарма Аг Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
CA2530114A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
WO2005082883A2 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
CA2568929A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
PL1841757T3 (pl) * 2005-01-07 2010-10-29 Pfizer Prod Inc Heteroaromatyczne związki chinoliny i ich zastosowanie jako inhibitorów PDE10
EP1838707B1 (en) * 2005-01-12 2009-04-29 Nycomed GmbH Novel pyrrolodihydroisoquinolines as pde10 inhibitors
JP2009535394A (ja) 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
CA2661992A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
BRPI0809244A2 (pt) * 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
JP2011505366A (ja) * 2007-11-30 2011-02-24 ワイス・エルエルシー ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン
AU2008329072A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
KR20110031355A (ko) 2008-06-25 2011-03-25 엔비보 파마슈티칼즈, 인코퍼레이티드 １,２―이치환된 헤테로사이클릭 화합물
WO2010006130A2 (en) 2008-07-09 2010-01-14 Envivo Pharmaceuticals, Inc. Pde-10 inhibitors
ES2654617T3 (es) 2008-08-05 2018-02-14 Omeros Corporation Inhibidores de PDE10 y composiciones y procedimientos relacionados
WO2010035745A1 (ja) * 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP2351748A4 (en) * 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
WO2010128995A1 (en) * 2009-05-07 2010-11-11 Envivo Pharmaceuticals, Inc. Phenoxymethyl heterocyclic compounds
JP2012526810A (ja) * 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
CA2792844C (en) * 2010-03-12 2014-12-09 Omeros Corporation Pde10 inhibitors and related compositions and methods
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CA2852820A1 (en) 2011-11-09 2013-05-16 AbbVie Deutschland GmbH & Co. KG Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
US9138494B2 (en) 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
UY34980A (es) 2012-08-17 2014-03-31 Abbvie Inc Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
KR20150056844A (ko) 2012-09-17 2015-05-27 아비에 도이치란트 게엠베하 운트 콤파니 카게 포스포디에스테라제 타입 10a의 신규 억제제 화합물
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
ES2723876T3 (es) 2013-02-27 2019-09-03 Mochida Pharm Co Ltd Nuevos derivados de pirazol
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
MX2015012008A (es) 2013-03-14 2016-04-15 Abbvie Deutschland Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN112996492A (zh) * 2018-09-05 2021-06-18 阿姆斯特丹大学 Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途
CN110346004B (zh) * 2019-08-16 2020-08-21 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法
KR20230040978A (ko) * 2020-06-05 2023-03-23 노에마 파르마 아게 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US5487976A (en) * 1993-10-15 1996-01-30 Cornell Research Foundation, Inc. DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
DE60210014T2 (de) * 2001-07-31 2006-09-21 Pfizer Products Inc., Groton Auf Zellen gegründetes Phosphodiesterase-10A-Assay und Sequenzen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657540C2 (ru) * 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств

Also Published As

Publication number Publication date
PL373943A1 (en) 2005-09-19
CA2484600A1 (en) 2003-11-13
RU2303259C2 (ru) 2007-07-20
TWI269812B (en) 2007-01-01
BR0309746A (pt) 2007-03-27
EP1504118A2 (en) 2005-02-09
US20030032579A1 (en) 2003-02-13
MXPA04010777A (es) 2005-03-07
CN1668761A (zh) 2005-09-14
KR20040106455A (ko) 2004-12-17
AU2003222395A1 (en) 2003-11-17
US20040162294A1 (en) 2004-08-19
TW200307751A (en) 2003-12-16
IL164778A0 (en) 2005-12-18
WO2003093499A2 (en) 2003-11-13
HRP20041029A2 (en) 2004-12-31
WO2003093499A3 (en) 2004-04-22
NO20044470L (no) 2004-11-04
JP2005524402A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
RU2004132198A (ru) Терапевтическое применение селективных ингибиторов pde10
JP2005524402A5 (ru)
Siwek et al. Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer’s disease
Tamagno et al. β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways
Upadhya et al. Role of the ubiquitin proteasome system in Alzheimer's disease
Disadee et al. Chirality Transfer from Guanidinium Ylides to 3-Alkenyl (or 3-Alkynyl) Aziridine-2-carboxylates and Application to the Syntheses of (2 R, 3 S)-3-Hydroxyleucinate and d-e rythro-Sphingosine
WO2002053577A3 (en) Gabaa modulating neurosteroids
TW200703444A (en) Substrate processing apparatus, history information recording method, history information recording program, and history information recording system
WO2009158467A3 (en) Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
WO2007028149A3 (en) Screening of inert solids from a low-yield wastewater treatment process
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
TW200604147A (en) Hydrocyanation
MXPA05010630A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios.
EP1787972A3 (en) Process for washing a distillation column used for the purification of (meth)acrylic acids
DK2005162T3 (da) Screeningsmetode
MA26350A1 (fr) Procede de traitement de concentre de molybdene contenant egalement du cuivre
ATE514724T1 (de) Verfahren zur bildung gradient (meth)acrylathaltiger präpolymere
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
DE69938067D1 (de) Verfahren zur Entfernung von organischen Verbindungen mittels Verbrennungskatalysatoren
EP1571127A3 (en) Production process for carbonized product and carbonized product obtained by the same process
WO2005016267A3 (en) Oxazole compounds for the treatment of neurodegenerative disorders
Qi et al. Preventing expression of the nicotinic receptor subunit α7 in SH-SY5Y cells with interference RNA indicates that this receptor may protect against the neurotoxicity of Aβ
FR2886867B1 (fr) Procede de fabrication d'un compose de type gel, pour le traitement d'effluent
FR2929876B1 (fr) Procede de traitement d'un element en bois d'une espece particuliere.
ATE338050T1 (de) Verfahren zur asymmetrischen hydrierung von ketocarbonsäureestern

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080423